NCT00195455

Study Evaluating Estradiol/Trimegestone in Vasomotor Symptoms (VMS) in Post-Menopausal Women.

A Prospective Open Label Study to Evaluate Vasomotor Symptoms Control and Bleeding Patterns With a Continuous Regimen of a New Progestin Trimegestone 0.125 mg and 17 b Estradiol 1 mg (Totelle),as HT on Postmenopausal Women

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 133 (estimated)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: Female
• Age: 45 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate vasomotor symptoms (VMS) control of the continuous regimen 17 b estradiol/trimegestone combination.

Conditions

• Postmenopause

Interventions

Type	Name	Description
DRUG	Trimegestone
DRUG	17b Estradiol

Timeline

• Start date: 2005-02-01
• Completion: 2007-03-01
• First posted: 2005-09-19
• Last updated: 2007-12-20

Locations

6 sites across 1 country: Mexico